Cure with SR18662 substantially decreases advancement and proliferation of CRC cells. SR18662 shows enhanced efficacy in minimizing viability of several CRC cell strains. Movement cytometry Evaluation pursuing SR18662 procedure displays an increase in cells captured in both S or G2/M phases of the mobile cycle and a substantial rise in the number o